Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer
1. RGNX released positive interim data from Phase 1/2 AFFINITY DUCHENNE trial. 2. RGX-202 showed consistent safety and functional benefits at 9 and 12 months. 3. Participants exceeded external controls in the North Star Ambulatory Assessment. 4. Biologics License Application is expected in mid-2026 for RGX-202. 5. RGNX stock dropped 11.2%, trading at $8.95 amid clinical developments.